Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma

Wang,Jizhen; Chen,Junmin; Qiu,Dongbiao; Zeng,Zhiyong

doi:10.3892/ijmm.2020.4831

Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma

Authors:
- Jizhen Wang
- Junmin Chen
- Dongbiao Qiu
- Zhiyong Zeng
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China, Department of Blood Transfusion, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, P.R. China
Published online on: December 24, 2020 https://doi.org/10.3892/ijmm.2020.4831
Pages: 643-658
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

DEPTOR, an inhibitor of mammalian target of rapamycin (mTOR), is essential for the survival of multiple myeloma (MM) cells. The expression level of DEPTOR is closely related to the prognosis of patients with MM treated with the antiangiogenic agent thalidomide; however, its role in the regulation of angiogenesis has not yet been elucidated. In the present study, the expression levels of DEPTOR and vascular endothelial growth factor (VEGF), and the microvessel density (MVD) of bone marrow (BM) from patients with MM assessed. DEPTORoverexpression plasmid or CRISPR‑associated protein 9 (Cas9) and single guided RNAs (sgRNAs) were used to modulate DEPTOR expression. The DEPTOR‑mediated angiogenic effects were assessed using a tube formation assay of human umbilical vein endothelial cells (HUVECs) cultured in the collected conditioned medium from MM cell lines with different expression levels of DEPTOR. It was found that the expression level of DEPTOR negatively correlated with the VEGF level and BM MVD in MM. Autophagic activity was regulated by DEPTOR expression, but was not related to thalidomide‑binding protein CRBN, which is required for thalidomide to play an anti‑tumor and antiangiogenic role in MM cells. The disruption of DEPTOR protein decreased cellular autophagy, increased VEGF expression in MM cells, and inhibited the tube formation of HUVECs, while a high expression of DEPTOR exerted the opposite effect. Moreover, targeting DEPTOR also resulted in the production of mitochondrial reactive oxygen species (mtROS), the phosphorylation of nuclear factor‑κB (NF‑κB) and an increase in interleukin 6 (IL‑6) secretion. Of note, these effects are fully abrogated by treatment with autophagy activator (SMER28) or mitochondrial‑specific antioxidant (Mito‑TEMPO). Taken together, the present study demonstrates the role of DEPTOR in the regulation of autophagy/mtROS and subsequent angiogenesis. The results provide a novel mechanism for the further understanding of the therapeutic effects of thalidomide on MM.

View Figures

View References

1	Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
2	Scott K, Hayden PJ, Will A, Wheatley K and Coyne I: Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 4:CD0108162016.PubMed/NCBI
3	Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, et al: Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexa-methasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX. Haematologica. 103:2088–2096. 2018. View Article : Google Scholar : PubMed/NCBI
4	Cao Y, Wan N, Liang Z, Xie J, Wang S, Lin T, Zhang T and Jiang J: Treatment outcomes in patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation: Systematic review and network meta-analysis. Clin Lymphoma Myeloma Leuk. 19:e478–e488. 2019. View Article : Google Scholar : PubMed/NCBI
5	Zeng Z, Lin J and Chen J: Bortezomib for patients with previously untreated multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Ann Hematol. 92:935–943. 2013. View Article : Google Scholar : PubMed/NCBI
6	André T, Kotelevets L, Vaillant JC, Coudray AM, Weber L, Prévot S, Parc R, Gespach C and Chastre E: Vegf, Vegf-B, Vegf -C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer. 86:174–181. 2000. View Article : Google Scholar
7	Kurebayashi J, Otsuki T, Kunisue H, Mikami Y, Tanaka K, Yamamoto S and Sonoo H: Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn J Cancer Res. 90:977–981. 1999. View Article : Google Scholar : PubMed/NCBI
8	Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C and Brambilla E: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival. J Pathol. 188:369–377. 1999. View Article : Google Scholar : PubMed/NCBI
9	Jussila L, Valtola R, Partanen TA, Salven P, Heikkilä P, Matikainen MT, Renkonen R, Kaipainen A, Detmar M, Tschachler E, et al: Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res. 58:1599–1604. 1998.PubMed/NCBI
10	Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F and Dammacco F: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 87:503–508. 1994. View Article : Google Scholar : PubMed/NCBI
11	Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS and Sabatini DM: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 137:873–886. 2009. View Article : Google Scholar : PubMed/NCBI
12	Zhao Y, Xiong X and Sun Y: DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell. 44:304–316. 2011. View Article : Google Scholar : PubMed/NCBI
13	de la Rubia J and Such E: DEPTOR expression and response to thalidomide: Toward a new therapeutic target in multiple myeloma? Leuk Lymphoma. 51:1960–1961. 2010. View Article : Google Scholar : PubMed/NCBI
14	Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE and Morgan GJ: High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma. 51:2126–2129. 2010. View Article : Google Scholar : PubMed/NCBI
15	Bruneau S, Nakayama H, Woda CB, Flynn EA and Briscoe DM: DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood. 122:1833–1842. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ding Y, Shan L, Nai W, Lin X, Zhou L, Dong X, Wu H, Xiao M, Zhou X, Wang L, et al: DEPTOR deficiency-mediated mTORc1 hyperactivation in vascular endothelial cells promotes angiogenesis. Cell Physiol Biochem. 46:520–531. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zhang H, Chen J, Zeng Z, Que W and Zhou L: Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro. Int J Mol Med. 31:1127–1134. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zhang HR, Chen JM, Zeng ZY and Que WZ: Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity. J Int Med Res. 41:584–595. 2013. View Article : Google Scholar : PubMed/NCBI
19	Cury PCC, Higashi F, Zacchi FFS, Palhares RB, Quero AA, Dias ALMS, Crusoé EQ and Hungria VTM: Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients. Hematol Transfus Cell Ther. 42:159–163. 2020. View Article : Google Scholar :
20	Redza-Dutordoir M and Averill-Bates DA: Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta. 1863:2977–2992. 2016. View Article : Google Scholar : PubMed/NCBI
21	Liu T, Zhang L, Joo D and Sun SC: NF-κB signaling in inflammation. Signal Transduct Target Ther. 2:170232017. View Article : Google Scholar
22	Sun K, Xu L, Jing Y, Han Z, Chen X, Cai C, Zhao P, Zhao X, Yang L and Wei L: Autophagy-deficient Kupffer cells promote tumorigenesis by enhancing mtROS-NF-κB-IL1α/β-dependent inflammation and fibrosis during the preneoplastic stage of hepatocarcinogenesis. Cancer Lett. 388:198–207. 2017. View Article : Google Scholar
23	Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, et al: The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol. 28:827–838. 2010. View Article : Google Scholar : PubMed/NCBI
24	Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI
25	Wang X, Lin Y, Song C, Sibille E and Tseng GC: Detecting disease-associated genes with confounding variable adjustment and the impact on genomic meta-analysis: With application to major depressive disorder. BMC Bioinformatics. 13:522012. View Article : Google Scholar : PubMed/NCBI
26	He W, Fu L, Yan Q, Zhou Q, Yuan K, Chen L and Han Y: Gene set enrichment analysis and meta-analysis identified 12 key genes regulating and controlling the prognosis of lung adenocarcinoma. Oncol Lett. 17:5608–5618. 2019.PubMed/NCBI
27	Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al: International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
28	Lee N, Lee H, Moon SY, Sohn JY, Hwang SM, Yoon OJ, Youn HS, Eom HS and Kong SY: Adverse prognostic impact of bone marrow microvessel density in multiple myeloma. Ann Lab Med. 35:563–569. 2015. View Article : Google Scholar : PubMed/NCBI
29	Quwaider D, Corchete LA, Misiewicz-Krzeminska I, Sarasquete ME, Pérez JJ, Krzeminski P, Puig N, Mateos MV, García-Sanz R, Herrero AB and Gutiérrez NC: DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. J Hematol Oncol. 10:922017. View Article : Google Scholar : PubMed/NCBI
30	Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, et al: High-resolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell. 9:313–325. 2006. View Article : Google Scholar : PubMed/NCBI
31	Mercurio A, Adriani G, Catalano A, Carocci A, Rao L, Lentini G, Cavalluzzi MM, Franchini C, Vacca A and Corbo F: A mini-review on thalidomide: Chemistry, mechanisms of action, therapeutic potential and anti-angiogenic properties in multiple myeloma. Curr Med Chem. 24:2736–2744. 2017. View Article : Google Scholar : PubMed/NCBI
32	Chen J, Zhu H, Liu Q, Ning D, Zhang Z, Zhang L, Mo J, Du P, Liu X, Song S, et al: DEPTOR induces a partial epithelial-to-mesenchymal transition and metastasis via autocrine TGFβ1 signaling and is associated with poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. 38:2732019. View Article : Google Scholar
33	Hu B, Shi D, Lv X, Wu F, Chen S and Shao Z: Prognostic and clinicopathological significance of DEPTOR expression in cancer patients: A meta-analysis. Onco Targets Ther. 11:5083–5092. 2018. View Article : Google Scholar : PubMed/NCBI
34	Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P and Czuczman MS: Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 140:36–45. 2008.
35	Haslett PA, Corral LG, Albert M and Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med. 187:1885–1892. 1998. View Article : Google Scholar : PubMed/NCBI
36	Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S and Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood. 108:618–621. 2006. View Article : Google Scholar : PubMed/NCBI
37	Sampaio EP, Sarno EN, Galilly R, Cohn ZA and Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 173:699–703. 1991. View Article : Google Scholar : PubMed/NCBI
38	Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP and Anderson KC: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood. 99:4525–4530. 2002. View Article : Google Scholar : PubMed/NCBI
39	Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW and Verhelle D: Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res. 69:7347–7356. 2009. View Article : Google Scholar : PubMed/NCBI
40	Hu Y, Su H, Liu C, Wang Z, Huang L, Wang Q, Liu S, Chen S, Zhou J, Li P, et al: DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia. Oncogene. 36:1038–1047. 2017. View Article : Google Scholar
41	Khandia R, Dadar M, Munjal A, Dhama K, Karthik K, Tiwari R, Yatoo MI, Iqbal HMN, Singh KP, Joshi SK and Chaicumpa W: A comprehensive review of autophagy and its various roles in infectious, non-infectious, and lifestyle diseases: Current knowledge and prospects for disease prevention, novel drug design, and therapy. Cells. 8:6742019. View Article : Google Scholar :
42	Koukourakis MI, Giatromanolaki A, Fylaktakidou K, Sivridis E, Zois CE, Kalamida D, Mitrakas A, Pouliliou S, Karagounis IV, Simopoulos K, et al: SMER28 is a mTOR-independent small molecule enhancer of autophagy that protects mouse bone marrow and liver against radiotherapy. Invest New Drugs. 36:773–781. 2018. View Article : Google Scholar : PubMed/NCBI
43	Roca-Agujetas V, de Dios C, Lestón L, Mari M, Morales A and Colell A: Recent insights into the mitochondrial role in autophagy and its regulation by oxidative stress. Oxid Med Cell Longev. 2019:38093082019. View Article : Google Scholar : PubMed/NCBI
44	Zhao L, Wang X, Yu Y, Deng L, Chen L, Peng X, Jiao C, Gao G, Tan X, Pan W, et al: OTUB1 protein suppresses mTOR complex 1 (mTORC1) activity by deubiquitinating the mTORC1 inhibitor DEPTOR. J Biol Chem. 293:4883–4892. 2018. View Article : Google Scholar : PubMed/NCBI
45	Wang Q, Zhou Y, Rychahou P, Harris JW, Zaytseva YY, Liu J, Wang C, Weiss HL, Liu C, Lee EY and Evers BM: Deptor is a novel target of Wnt/β-catenin/c-Myc and contributes to colorectal cancer cell growth. Cancer Res. 78:3163–3175. 2018. View Article : Google Scholar : PubMed/NCBI
46	Catena V and Fanciulli M: Deptor: Not only a mTOR inhibitor. J Exp Clin Cancer Res. 36:122017. View Article : Google Scholar : PubMed/NCBI
47	Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M and Sezer O: Angiogenesis in multiple myeloma. Eur J Cancer. 42:1581–1590. 2006. View Article : Google Scholar : PubMed/NCBI
48	Khan MA, Assiri AM and Broering DC: Complement and macrophage crosstalk during process of angiogenesis in tumor progression. J Biomed Sci. 22:582015. View Article : Google Scholar : PubMed/NCBI
49	Padmanaban V, Krol I, Suhail Y, Szczerba BM, Aceto N, Bader JS and Ewald AJ: E-cadherin is required for metastasis in multiple models of breast cancer. Nature. 573:439–444. 2019. View Article : Google Scholar : PubMed/NCBI